Subscribe to Get Prostate Cancer News

Subscribe

HotSheets by Year

Hot SHEET 2021

Current Issue: July 2021

The most recent Hot SHEET
  • Is Abiraterone + ADT + Docetaxel a New Standard of Care for mCSPC?
  • Prostate Cancer Care Declined During the COVID-19 Pandemic
  • PCa Genome Differs by Ancestry but Actionable Alterations Are Similar
  • Inverse Stage Migration in RP – a Sustaining Phenomenon
  • Time Trends in Use of RP by Tumor Risk and Life Expectancy in the VA
  • Dr. Moyad's No Bogus Science: "Lycopene vs. Asparagus?!"
  • Bone-Protecting Agents (BPAs) Cut Fracture Risk in Metastatic PCa
  • EPO No Help for Preventing Erectile Dysfunction After RP
  • Artificial Intelligence for RT Planning Works, but is it Fully Trusted?
  • No Need to Raise Salvage Radiation Therapy Dose After RP
  • Adjuvant vs. Early Salvage RT Post-RP in Men with High-Risk PCa
  • Quantitative Total Bone Imaging in PCa: Novel Technology

See past issues below…

Made possible by charitable contributions from

BAYER
Accuray
AAA
Clovis Oncology
 

 - Thank You!

 

Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Subscribe to get the Hot SHEET (and other prostate cancer news and information) for free via email from Us TOO at www.ustoo.org/subscribe.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.



  • High-Risk PCa Patients Can Wait Six Months for Surgery
  • FDA OKs "Game Changer" Radiotracer for PCa Imaging
  • FDA Approves Relugolix (ORGOVYX®) for Advanced PCa
  • RP with/without Neoadjuvant Chemohormonal Treatment
  • FoundationOne Liquid Companion Diagnostic Approved for Olaparib
  • Doc Moyad's No Bogus Science: "Vegan = Magic?!"
  • Artificial Intelligence for Detecting Bone Metastases
  • Genomic Profiles of High/Low Volume Metastatic PCa in STAMPEDE
  • Model Compares Cost of IsoPSA™ vs. Repeat Biopsies
  • Financial Toxicity of PCa Treatment
  • Index of Articles Published in 2020 Hot SHEETs
  • Geography Seen as Factor in Overtreatment of Low-Risk PCa
  • Statins Tied to Better Outcomes When Starting Androgen Deprivation
  • AI Tool for Precision PCa Treatment
  • Race Decisional Regret & PCa Beliefs
  • Urine Exosome Gene Expression Panel & Indolent vs. Aggressive PCa
  • Doc Moyad's No Bogus Science: "Dog Health = Human Health?!"
  • Detection Rate of PSMA Tracers for PET/CT in PSA Recurrence
  • Higher Coffee Intake & Risk of PCa
  • POP-RT Trial & Whole Pelvis RT for High-Risk Prostate Cancer
  • ProCAID: Capivasertib & Docetaxel & Prednisolone in Metastatic CRPC
  • Cost Effectiveness of Prostate RT for Low Burden Metastatic PCa
  • 4Kscore®, ExosomeDx™ & MRI for High-Grade PCa Detection
  • Circulating Tumor Cells & Response to Radium-223 in Metastatic CRPC
  • Greater Subcutaneous Fat Improves mCRPC Treatment Response
  • Prostate Radiotherapy with ADT Improves Metastasis-Free Survival
  • PSA – Here’s Your Competition for Prostate Cancer Screening
  • Hit & Miss in Castration-Resistant Prostate Cancer Treatment
  • CCR Score Could Offer ADT-Free Path in High-Risk Prostate Cancer
  • ED Is a Transient Complication of Prostate Biopsy: A Systematic
  • MRI-Guided Prostate Biopsy Prevails in PRECISE Trial
  • Dr Moyad's No Bogus Science: "Move More = Sleep Better + Dogs?!"
  • RT's Role in Metastatic PCa Clarified
  • Radionuclide Treatment Wins in Third-Line Treatment of mCRPC
  • Decipher Test May Guide Post-Op Treatment in Prostate Cancer
  • Combination Treatment Disappoints in Metastatic CRPC
  • Androgen Annihilation & Prolonged Survival in mCRPC
  • Sniffer Dogs from Great Britain Have a Nose for Prostate Cancer
  • Medications for Enlarged Prostatic Gland Linked to Heart Failure Risk
  • Prostate Radiofrequency Focal Ablation (ProRAFT) Therapy for PCa
  • Final TITAN Study Results Confirm Apalutamide Benefit in mCRPC
  • Dr Moyad’s No Bogus Science: "Viva Artichoke Season?!"
  • CCR Score Can Guide Treatment After Radiation Treatment in PCa
  • Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC
  • No Benefit of Dose Intensified Salvage RT for PCa Recurrence
  • Androgen Cycling Shows Promise in Castration Resistant Prostate Cancer
  • More Benefit with Taxane for Aggressive Metastatic PCa
  • Prostate RT Tied to Improved Survival in Newly Diagnosed mHSPC
  • Healthy Lifestyle May Offset Genetic Risk in Prostate Cancer
  • Transperineal Prostate Biopsy and Detection of Clinically Significant PCa
  • Genomic Testing and Treatment Decisions in African American Men
  • Doc Moyad's No Bogus Science: "The Chicken, Egg, or Lifestyle?!"
  • Therapies for Clinically Localized PCa
  • Estimated Projection of US Cancer Incidence and Death to 2040
  • Patient-Reported Health Status, Comorbidity Burden, and PCa Treatment
  • Jump in Cancer Diagnoses at 65 Implies Patients Wait for Medicare
  • Inadequacies in Genetic Testing Referrals and Counseling in PCa
  • Benefit, Harm, and Cost-Effectiveness of MRI Before Biopsy in PCa Screening
  • Additional Treatment Option in PCa
  • MRI-Targeted and Systematic Biopsy for Detecting Grade Progression during AS
  • Many Americans Put Off Cancer Screenings Because of COVID-19
  • Stereotactic Body RT Safe for PCa Patients with Multiple Metastases
  • Late ADT a Problem in PCa
  • Negative Follow-Up Biopsy and Reclassification During AS
  • Apalutamide vs. mCRPC: Final Results of Phase 3 TITAN Study
  • Dr. Moyad's No Bogus Science: "Football for Metastatic PCa?!"
  • Choice of ED Medication May Have Heart Health Implications
  • Bone Mineral Density Changes and Long-Term ADT in Localized PCa
  • Salvage CRYO for Recurrent PCa
  • Unexpected Race Based Findings in Novel PCa Study
  • Radiotracer Boosts PCa Outcomes
  • PCa Polygenic Risk Score with Number and Laterality of Tumor Cores in AS Patients
  • Genomic Prostate Score and AS



 
  • Is Abiraterone + ADT + Docetaxel a New Standard of Care for mCSPC?
  • Prostate Cancer Care Declined During the COVID-19 Pandemic
  • PCa Genome Differs by Ancestry but Actionable Alterations Are Similar
  • Inverse Stage Migration in RP – a Sustaining Phenomenon
  • Time Trends in Use of RP by Tumor Risk and Life Expectancy in the VA
  • Dr. Moyad's No Bogus Science: "Lycopene vs. Asparagus?!"
  • Bone-Protecting Agents (BPAs) Cut Fracture Risk in Metastatic PCa
  • EPO No Help for Preventing Erectile Dysfunction After RP
  • Artificial Intelligence for RT Planning Works, but is it Fully Trusted?
  • No Need to Raise Salvage Radiation Therapy Dose After RP
  • Adjuvant vs. Early Salvage RT Post-RP in Men with High-Risk PCa
  • Quantitative Total Bone Imaging in PCa: Novel Technology